STIM
INSIDER BUYNeuronetics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveNeuronetics delivered a strong Q2 2026 earnings beat with revenue of $41.6M (+9.1% YoY), dramatically narrowed net losses to $3.4M, and achieved positive adjusted EBITDA of $0.3M, driving a 24% stock surge. Management raised FY2026 gross margin guidance and lowered opex while modestly narrowing revenue guidance, supported by Greenbrook clinic momentum (+16.8% YoY) and new NeuroStar commercial models, though core NeuroStar revenue declined 2.7% YoY.
Red flags
- •NeuroStar product revenue declined 2.7% YoY despite overall growth being clinic-driven
- •Management warned of 'more variable' second-half revenue during transition period
- •Still unprofitable on net income basis and cash flow guidance shows negative $10.5M–$14.5M range for full year
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).